DanielJohnsonMD

Oncology • New Orleans, LA

Hematology Oncology Fellow

Join to view full profile

Dr. Johnson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Johnson's full profile

Already have an account?

Office
1514 Jefferson Hwy
New Orleans, LA 70121
Phone+1 504-842-2873

Fax+1 504-842-4533

Education & Training

Louisiana State University School of Medicine in New OrleansClass of 2012
Louisiana State UniversityFellowship, Medical Oncology
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology

Certifications & Licensure

LA State Medical License 2019 - 2025
AL State Medical License 2020 - 2024
MS State Medical License 2019 - 2020
TX State Medical License 2017 - 2020
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

30 citations
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.
Faisal Fa'ak, Maryam Buni, Adewunmi Falohun, Huifang Lu, Juhee Song
Journal for Immunotherapy of Cancer. 2023-06-01
Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration.
Yifan Zhou, Yusra B Medik, Bhakti Patel, Daniel B Zamler, Sijie Chen
The Journal of Experimental Medicine. 2023-02-06
135 citations
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.
Yared Hailemichael, Daniel H Johnson, Noha Abdel-Wahab, Wai Chin Foo, Salah-Eddine Bentebibel
Cancer Cell. 2022-05-09

Lectures

Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity.
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

Q&A: The Evolving Role of Antibody-Drug Conjugates in OncologyAugust 20th, 2024
NanoString Highlights Research Presented at the 2018 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)November 7th, 2018
Single-Payer Healthcare, Obesity Drug Coverage Discussed at the AMA Interim MeetingNovember 14th, 2023